Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- (-) Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- (-) Real-World Data
- (-) Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- (-) Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Audience
Audience
Display Only
Showing 214 Results
National Pharmaceutical Council Appoints John M. O’Brien as President and CEO
Veteran drug pricing and health policy expert John M. O’Brien, Pharm.D., MPH, has been appointed as president and chief executive officer of the National Pharmaceutical Council, effective June 1,…
U.S. vs. EU: Not a Direct Comparison When It Comes to Drug Pricing
It’s challenging to compare U.S. and ex-U.S. countries’ drug prices and health spending, given the big differences in the countries’ economies, health care systems, payment mechanisms and disease…
Stakeholders Find Step Therapy Should Be Evidence-Based, Flexible and Transparent: Assessing Appropriateness Using a Consensus Approach
Stakeholders disagree on when step therapy is appropriate, but agree on a set of criteria about how to develop, implement, communicate, safeguard and evaluate step therapy protocols.
If You Must Do Step Therapy, Do It Right
Finding consensus among health care stakeholders is never easy, and that is certainly true when it comes to the use of care management tools. But there are areas of agreement, especially if we focus…
NPC Comments on Most Favored Nation (MFN) Model [CMS-5528-IFC]
NPC explains how using payment models based on pricing in other countries could have a negative impact on patient outcomes, access to treatments and future innovation.
What’s In Your RWE Evaluation Toolbox?
Real-world evidence (RWE) – information collected from everyday health care experiences – is growing in availability, and many health care decision-makers are interested in understanding and using…
The American Journal of Managed Care® Adds National Pharmaceutical Council to Strategic Alliance Partnership Program
The American Journal of Managed Care® (AJMC®) and Pharmacy Times® today announced that the National Pharmaceutical Council (NPC) has joined their Strategic Alliance Partnership (SAP) programs.
Online Tools to Synthesize Real-World Evidence of Comparative Effectiveness Research to Enhance Formulary Decision Making
The authors describe and compare the features and characteristics of five tools to evaluate real-world evidence studies and add clarity on what the tools provide.
Assessing Consumer and Employer Willingness to Pay for New Medical Technologies
This study examines whether health care consumers and large employers would be willing to continue to pay for new medical technologies associated with significant improvements in patient health…
Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing—Why, What, and How Recommendations and a Roadmap from the Real-World Evidence Transparency Initiative
A position paper by the RWE Transparency Initiative describes a plan for improving the transparency of the research process and making registration of real-world evidence study methods easier…
National Pharmaceutical Council Names Dr. Robert Dubois as Interim President and CEO
As interim president and CEO, Dr. Robert Dubois plans to focus on two priorities: continuing to leverage NPC's ongoing evidence-based research, partnerships and education, and preparing for future…
Building on NPC’s Commitment to Sound Health Policy Research and Evidence-based Dialogue
As the interim leader of NPC, Dr. Robert Dubois is focused on two priorities: continuing to leverage NPC's evidence-based research, partnerships, and education, and preparing for future policy…
AARDA’s Randy Rutta Talks Step Therapy
In this Q&A, Randy Rutta, AARDA’s President and CEO, talks about his organization’s efforts to raise awareness about step therapy and opportunities for patient-centered reforms.
NPC Weighs in on NQF’s Draft Report on Patient-Reported Outcomes
The National Pharmaceutical Council (NPC) submitted comments to the National Quality Forum (NQF) regarding the Patient-Reported Outcomes: Best Practices on Selection and Data Collection draft…
Lessons from COVID-19: Step Therapy Should Not Be a Barrier to Patient Access
Step therapy requires patients to try a clinically recognized, lower cost first-line therapy before receiving reimbursement for an alternative therapy prescribed by the physician and can delay access…
National Pharmaceutical Council and Duke-Margolis Center for Health Policy Announce New Health Policy Fellow
Dr. Salama Freed has been named NPC/Duke-Margolis Health Policy Fellow for 2020-22.
National Pharmaceutical Council 2019 Annual Report
NPC's 2019 annual report outlines how the organization is driving discussions on some of the most complex topics in health care policy.
A Wish List for the Health Care Sector in 2020
NPC President and CEO Dan Leonard reflects on the health policy issues he hopes will be addressed in 2020.